In a press release on the survey results, Presidio said CEOs of Biotech companies saw an 11% increase in total cash compensation. However, a median 8.5% decrease in stock prices led to lower stock option grant values.
Other findings of the survey, according to the release, include:
- Use of restricted stock nearly tripled from one year ago, with 35% of companies in the survey granting restricted stock to at least one executive.
- Restricted stock grants to Chief Executive Officers doubled to 27% of CEOs receiving the increasingly popular long-term incentive.
- For the top six highest paid executive positions, two-thirds of the total compensation package was “at-risk” pay linked to company and executive performance through annual bonuses and long-term incentives.
Presidio analyzed executive compensation and ownership levels in 67 companies in the Biotech industry for the survey.